Pharma-Telehealth Link: A $10 Script for Your Libido

A $10 telehealth visit, a special code, and a prescription for a little pink pill. That's the new reality for women seeking to boost their libido with Addyi, a drug that just got a major market expansion. But beneath the discount lies a controversial alliance between pharma and telemedicine that critics say undermines independent medical judgment.

The Science

Addyi (flibanserin) was approved by the FDA in 2015 for hypoactive sexual desire disorder (HSDD) in premenopausal women, following a contentious review. Its mechanism involves modulating serotonin and dopamine receptors in the brain, but clinical benefits are modest: on average, women experience 0.5 to 1 additional satisfying sexual event per month compared to placebo. However, the dropout rate due to adverse effects was 13% versus 6% with placebo, highlighting the need for careful evaluation. In December 2025, the FDA expanded approval to all women under 65, effectively doubling the eligible population. This expansion was based on post-marketing studies showing similar efficacy and safety in postmenopausal women, though critics argue the data are still limited.

Sprout Pharmaceuticals, Addyi's maker, now offers a telehealth consultation for just $10 using the code PINKPILL. The service is run by Prescribery, a telehealth company that receives fees from drugmakers to connect patients with prescribers. According to CEO Ross Pope, "We give them the coupon codes that they can use, and they get to market it to drive additional business." This arrangement raises questions about whether the consultation is truly independent or merely a script-delivery mechanism. A 2024 investigation by the Kaiser Family Foundation found that similar pharma-funded telehealth programs for other drugs led to higher prescribing rates without corresponding increases in appropriate diagnoses.